Sarepta Therapeutics (NASDAQ:SRPT) Earns “Market Perform” Rating from William Blair
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “market perform” rating reissued by equities researchers at William Blair in a report issued on Friday, Marketbeat reports. Several other brokerages have also recently weighed in on SRPT. JPMorgan Chase & Co. decreased their price objective on Sarepta Therapeutics from $169.00 to $84.00 and set […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “market perform” rating reissued by equities researchers at William Blair in a report issued on Friday, Marketbeat reports. Several other brokerages have also recently weighed in on SRPT. JPMorgan Chase & Co. decreased their price objective on Sarepta Therapeutics from $169.00 to $84.00 and set […]
